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To adjust adequately for comorbidity and severity of illness in
quality improvement efforts and prospective clinical trials,
predictors of death after acute renal failure (ARF) must be
accurately identified. Most epidemiological studies of ARF in
the critically ill have been based at single centers, or have
examined exposures at single time points using discrete
outcomes (e.g., in-hospital mortality). We analyzed data from
the Program to Improve Care in Acute Renal Disease
(PICARD), a multi-center observational study of ARF. We
determined correlates of mortality in 618 patients with ARF in
intensive care units using three distinct analytic approaches.
The predictive power of models using information obtained
on the day of ARF diagnosis was extremely low. At the time of
consultation, advanced age, oliguria, hepatic failure,
respiratory failure, sepsis, and thrombocytopenia were
associated with mortality. Upon initiation of dialysis for ARF,
advanced age, hepatic failure, respiratory failure, sepsis, and
thrombocytopenia were associated with mortality; higher
blood urea nitrogen and lower serum creatinine were also
associated with mortality in logistic regression models.
Models incorporating time-varying covariates enhanced
predictive power by reducing misclassification and
incorporating day-to-day changes in extra-renal organ system
failure and the provision of dialysis during the course of ARF.
Using data from the PICARD multi-center cohort study of ARF
in critically ill patients, we developed several predictive
models for prognostic stratification and risk-adjustment. By
incorporating exposures over time, the discriminatory power
of predictive models in ARF can be significantly improved.
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In critically ill patients, acute renal failure (ARF) is associated
with mortality rates in excess of 50%,1–3 despite increasing
availability of sophisticated intensive care, hemodialysis, and
hemodiafiltration. Over the past two decades, numerous
observational studies have aimed to identify clinical
predictors of mortality in ARF. Some have attempted to
validate generic or disease-specific predictive instruments;4–13
others have derived new predictive models;14–17 and most
have been developed from single centers9,10,14 and have
examined risk factors at a single point in time.8,15,18
In an effort to develop a registry of critically ill patients
with ARF across multiple clinical sites, we created the
Program to Improve Care in Acute Renal Disease (PICARD).
The major goal of PICARD was to leverage the diversity
of several sites and a relatively large sample of patients to
better understand the demographic, process, renal, and extra-
renal factors associated with relevant clinical outcomes,
including mortality, non-recovery of kidney function,
and resource utilization. In doing so, our hope was to
provide a contemporary view of the ARF disease process
and to generate hypotheses that might be eligible for testing
in prospective clinical trials (e.g., medication use, dialysis
modality and timing, nutritional therapy, etc.).
Herein, we provide a comprehensive analysis of demo-
graphic and clinical factors associated with mortality in the
618 patients enrolled in PICARD. To extend previously
published work in this area, we aimed to provide predictive
models at three key time points during the course of ARF – on
the day of ARF diagnosis, on the day of consultation, and in a
subcohort, on the day of initiation of dialysis or hemodia-
filtration – as well as to provide an integrated approach taking
advantage of longitudinal data collection, using models
incorporating time-varying covariates. We hypothesized that
oliguria, sepsis, respiratory failure, and hepatic failure would
be consistently associated with mortality.
RESULTS
Six hundred and eighteen patients were enrolled in PICARD.
Table 1 shows a summary of demographic and clinical
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characteristics at three key time points during the course of
ARF in the intensive care unit (ICU). The cohorts for the day
of ARF diagnosis and day of consultation were identical;
demographic and historical information were by definition
identical; however, dynamic characteristics (e.g., organ fail-
ure, vital signs, and laboratory results) changed over time.
Three hundred and ninety-eight (64%) patients required
initiation of dialysis. Although inference tests were not
conducted, one can appreciate that the subcohort requiring
dialysis tended to have more significant azotemia, lower urine
output, and tended to have more extensive organ system
failure, particularly of the lungs and liver, than the full
PICARD cohort. Nearly one-third of patients had evidence of
significant baseline chronic kidney disease (CKD).
Predictors at discrete time points
Day of ARF diagnosis. Figure 1 demonstrates in-hospital
mortality rates from the day of ARF diagnosis. Tables 2 and 3
show logistic regression and proportional hazards regression
models for the outcomes in-hospital death within 60 days,
and the time to death within 60 days, respectively,
considering the day of ARF diagnosis as the specified time
point. Advanced age, liver failure, and higher blood urea
nitrogen (BUN) concentrations at the time the creatinine-
based ARF criteria were met were associated with mortality
using both statistical methods. In the logistic regression
model, baseline CKD was associated with lower, and sepsis
associated with higher, risks of death. These factors did not
reach statistical significance in the proportional-hazards
models. Model discrimination was relatively poor; the area
under the receiver operating characteristic (ROC) curves for
death was 0.62. The model was well calibrated.
Day of consultation. Analogous models considering the
day of nephrology consultation as the specified time point are
also shown in Tables 2 and 3. Advanced age and liver failure
remained significant predictors of death; in addition,
parameters of kidney function and extra-renal organ system
failure were also associated with the risk of death. When
evaluated on the day of consultation, patients with lower
urine output, serum creatinine o2.0 mg/dl, and higher BUN
were at increased risk of death, confirming findings described
in a single-center cohort predating PICARD.22 Adult
respiratory distress syndrome (defined as a ratio of oxygen
tension to fractional inspired oxygen concentration (paO2/
FIO2) o200 mm Hg), sepsis, and relative thrombocytopenia
(o150 106/l) were also significant predictors of death. The
area under the ROC curve for the day of consultation model
was considerably higher than for the day of ARF diagnosis
models – 0.68 – and the model was well calibrated.
Day of initial dialysis procedure. Predictors of mortality
among the subcohort of 398 patients who required dialysis
during the ICU stay are also shown in Tables 2 and 3. As with
the previous two key time points, advanced age and liver
failure were significantly associated with mortality among
patients with ARF requiring dialysis. In contrast to the day of
consultation models, urine output was not associated with
mortality when evaluated on the day of dialysis initiation.
The mean serum creatinine and BUN at dialysis initiation
were 4.5 mg/dl (10, 90% range 2.3–7.5 mg/dl) and 86 mg/dl
(10, 90% range 34–142 mg/dl), respectively. Lower serum
creatinine and higher BUN concentrations were associated
with an increased risk of mortality. The day of dialysis
Table 1 | Patient characteristics at the day of ARF diagnosis,
consultation, and first procedure
Parameter
Day of ARF
diagnosis
(n=618)
Day of
consultation
(n=618)
Day of first
procedure
(n=398)
Mean age (years) 59 59 57
% Female 41 41 42
Race/ethnicity
Caucasian 80% 80% 78%
African American 8% 8% 7%
Asian 6% 6% 8%
Hispanic 4% 4% 5%
Other 2% 2% 2%
% History of CKD, stage IV
or above
32 32 36
% Surgery pre/at ICU admission 38 38 35
% History of hypertension 53 53 48
% History of diabetes mellitus 29 29 27
% History of COPD 16 16 15
% History of heart failure 28 28 26
% History of coronary artery
disease
37 37 30
Mean no. of organ systems failed 2.7 2.9 3.1
% Central nervous system failure 21 20 24
% Liver failure 29 31 39
% Hematologic failure 27 25 30
% Cardiovascular failure 48 49 46
% Respiratory failure 42 60 68
% Mechanical ventilation 33 47 36
% Acute lung injury 30 47 45
% ARDS 19 30 30
% Sepsis or septic shock 26 29 37
Mean heart rate (per min) 95 95 96
% Tachycardia 60 39 42
Mean systolic BP (mm Hg) 115 115 114
Mean diastolic BP (mm Hg) 58 56 56
Mean arterial BP (mm Hg) 77 76 75
Mean pulse pressure (mm Hg) 57 59 58
Mean temperature (1C) 37 37 36.9
Median urine output (ml) 1150 1258 800
% Oliguria (p400 ml/day) 27 29 49
Mean respiratory rate 20 20 20
Mean AM weight (kg) 86 87 90
Median total bilirubin (mg/dl) 1.5 1.7 2.4
Mean creatinine (mg/dl) 2.8 3.4 4.5
Mean BUN (mg/dl) 54 65 86
Mean platelets (1000/mm3) 175 155 146
% Thrombocytopenic
(o150 106/l)
49 57 62
Mean pH 7.3 7.4 7.3
Mean potassium (mEq/l) 4.6 4.6 4.6
Mean bicarbonate (mEq/l) 21.9 21.4 20.3
Mean leukocyte (1000/mm3) 14 14 14.9
Mean hemoglobin (g/dl) 10.5 10.2 10.1
AM, adrenomedullin; ARDS, adult respiratory distress syndrome; ARF, acute renal
failure; BP, blood pressure; BUN, blood urea nitrogen; CKD, chronic kidney disease;
COPD, chronic obstructive pulmonary disease; ICU, intensive care unit.
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initiation ranged from 0 to 43 days after ARF diagnosis and
0 to 31 days after nephrology consultation.
The provision of dialysis. In Table 4, we show predictors of
dialysis from the day of diagnosis and the day of consultation
using logistic regression. As expected, lower urine output and
higher BUN were associated with the use of dialysis during
the ARF episode. Interestingly, older patients were less likely
to receive dialysis. Although older age was associated with
mortality, early deaths among the elderly (i.e., before dialysis
could be provided) did not account for the difference in
dialysis practice.
Comparison with generic severity of illness scores. Table 5
shows areas under the ROC curves and likelihood ratios for
the models described above (denoted ‘PICARD’) and 11
1.00
0.75
0.50
0.25
0.00
Su
rv
iva
l d
ist
rib
ut
io
n 
fu
nc
tio
n
0 10 20 30 40 50 60
# Days from ARF start to
death/discharge (truncated at 60)
# Days post ARF start
7 days n = 549
14 days n = 419
21 days n = 302
28 days n = 228
35 days n = 159
42 days n = 118
60 days n = 61
Figure 1 | In-hospital mortality rates within 60 days after ARF
diagnosis.
Table 2 | Predictors of mortality using logistic regression
Parameter Coefficient OR 95% CI
Day of ARF diagnosisa
Intercept 1.5023 — —
Age (per 10 years) 0.1055 1.11 1.00–1.24
CKD stage IV 0.5555 0.57 0.39–0.84
BUN (per 10 mg/dl) 0.0568 1.06 1.00–1.12
Liver failure 0.4628 1.59 1.03–2.44
Sepsis or septic shock 0.5908 1.81 1.20–2.72
Day of consultationb
Intercept 1.2563 — —
Age (per 10 years) 0.1241 1.13 1.01–1.27
Log urine output 0.2063 0.81 0.72–0.93
Creatinine o2 mg/dl 0.6900 1.99 1.18–3.36
BUN (per 10 mg/dl) 0.0828 1.09 1.03–1.14
Liver failure 0.4811 1.62 1.09–2.41
ARDS 0.5800 1.79 1.23–2.60
Platelets o150 106/l 0.5074 1.66 1.17–2.36
Sepsis or septic shock 0.4083 1.50 1.02–2.22
Day of first procedurec
Intercept 1.9506 — —
Age (per 10 years) 0.1444 1.16 1.00–1.34
Creatinine (per 1 mg/dl) 0.2091 0.81 0.72–0.92
BUN (per 10 mg/dl) 0.0860 1.09 1.03–1.15
Liver failure 0.5655 1.76 1.09–2.85
Respiratory failure 0.6100 1.84 1.11–3.04
Platelets o100 106/l 0.7436 2.10 1.33–3.33
Sepsis or septic shock 0.5216 1.69 1.04–2.72
ARDS, adult respiratory distress syndrome; ARF, acute renal failure; BUN, blood urea
nitrogen; CI, confidence interval; CKD, chronic kidney disease; OR, odds ratio; ROC,
receiver operating characteristic.
aArea under ROC curve=0.62, Hosmer–Lemeshow w2=0.20.
bArea under ROC curve=0.68, Hosmer–Lemeshow w2=0.67.
cArea under ROC curve=0.72, Hosmer–Lemeshow w2=0.16.
Note: Different expressions of related variables included in individual models based
on model performance and fit (e.g., plateletso150 106/l vso100 106/l, discrete
vs continuous creatinine in the day of consultation and day of procedure models).
Table 3 | Predictors of mortality using proportional hazards
(Cox) regression
Parameter Coefficient RR 95% CI
Day of ARF diagnosisa
Age (per 10 years) 0.0942 1.10 1.00–1.20
BUN (per 10 mg) 0.0466 1.05 1.01–1.09
Liver failure 0.6559 1.93 1.41–1.63
Day of consultationb
Age (per 10 years) 0.1124 1.12 1.02–1.22
Log urine output (ml/day) 0.1176 0.89 0.81–0.97
Creatinine o2 mg/dl 0.4621 1.59 1.09–2.30
BUN (per 10 mg/dl) 0.0560 1.06 1.02–1.09
Liver failure 0.4856 1.63 1.22–2.17
ARDS 0.3413 1.41 1.07–1.85
Platelets o150 106/l 0.3217 1.38 1.05–1.81
Day of first procedurec
Age (per 10 years) 0.1250 1.13 1.02–1.26
Liver failure 0.4827 1.62 1.18–2.23
Platelets o100 106/l 0.4934 1.64 1.20–2.23
Sepsis or septic shock 0.4823 1.62 1.19–2.20
ARDS, adult respiratory distress syndrome; ARF, acute renal failure; BUN, blood urea
nitrogen; CI, confidence interval; RR, risk ratio.
aNote: The baseline survival function at 30 days was 0.711 and at 60 days was 0.518.
The mean values of the non-discrete variables were age 54.4 years and BUN
54.0 mg/dl. Likelihood ratio=23.3.
bNote: The baseline survival function at 30 days was 0.771 and at 60 days was 0.619.
The mean values of the non-discrete variables were age 52.9 years, and BUN
67.7 mg/dl and log urine output 6.13 ml/day. Likelihood ratio=47.1.
cNote: The baseline survival function at 30 days was 0.782 and at 60 days was 0.621.
The mean value of the non-discrete variable was age 52.9 years. Likelihood
ratio=33.4.
Table 4 | Predictors of the need for dialysis
Parameter Coefficient OR 95% CI
Day of ARF diagnosisa
Intercept 4.0685 — —
Age (per 10 years) 0.1978 0.82 0.73–0.92
Log urine output 0.4028 0.67 0.55–0.81
BUN (per 10 mg/dl) 0.0609 1.06 1.00–1.13
Liver failure 0.6012 1.82 1.11–3.00
Day of consultationb
Intercept 7.1449 — —
Age (per 10 years) 0.2344 0.79 0.70–0.89
Log urine output 0.8709 0.42 0.34–0.51
BUN (per 10 mg/dl) 0.1012 1.11 1.05–1.17
Liver failure 0.5311 1.70 1.08–2.67
ARF, acute renal failure; BUN, blood urea nitrogen; CI, confidence interval; OR, odds
ratio.
aArea under ROC curve=0.68, Hosmer–Lemeshow w2=0.75.
bArea under ROC curve=0.77, Hosmer–Lemeshow w2=0.46.
Note: The areas under the ROC curve were significantly different (Po0.05) for the
day of ARF diagnosis and day of consultation.
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other predictive equations – eight generic and three ARF
specific (Cleveland Clinic Foundation (CCF), Stuivenberg
Hospital Acute Renal Failure, and Lian˜o equations). It should
be noted that several of the predictive equations were
specifically developed at discrete time points (e.g., acute
physiology and chronic health evaluation (APACHE) II upon
ICU admission, CCF upon initiation of dialysis in the ICU),
and the relative performance of the models vs the PICARD
model may reflect the timing of model derivation. For
example, the CCF score was developed among patients with
ARF requiring dialysis. The predictive power of the CCF
model was poor when applied on the day of ARF diagnosis,
but very good when applied on the day of dialysis initiation.
Among existing generic predictive models, the sequential
organ failure assessment (SOFA) score (with the ‘renal’ SOFA
organ system included) performed most favorably, particu-
larly at the two later time points.
Time-dependent covariate analyses. Table 6 shows the
results of proportional hazards regression models exploring
time to death (with censoring at discharge or hospital day
60). Using integrated exposure data, the risk of mortality was
associated with older age, sepsis, and the presence of central
nervous system, cardiovascular, liver, and hematologic fail-
ure. The provision of dialysis was associated with an
increased risk of death. In companion models where
parameters of kidney function (rather than dialysis) were
included as candidate variables, higher serum creatinine
concentrations and oliguria were significantly associated with
mortality; in these models, parameter estimates for the extra-
renal covariates were virtually identical (data not shown).
DISCUSSION
Herein, we provide a comprehensive evaluation of risk factors
for mortality in the PICARD multi-center cohort study of
critically ill patients with ARF. In contrast to other studies, in
which a single discrete time point during the course of ARF
was examined, we examined three key time points – the day
of ARF diagnosis, the day of consultation, and in the subset
of patients who required dialysis, the day of first procedure.
All generic and disease-specific models performed relatively
poorly early in the course of ARF. With established ARF (on
the day of consultation), or ARF requiring dialysis, many of
the models’ predictive power improved significantly.
The ability to predict accurately in-hospital mortality in
patients with ARF is important for several reasons. First,
objective data can be employed in shared medical decision-
making, to the benefit of practitioners, patients, and their
families. Second, policy makers and practitioners can use
prognostic models for quality improvement by objectively
evaluating relative performance among ICUs, hospitals, or
larger health-care delivery systems. Finally, knowledge of the
key factors associated with mortality in critically ill patients
with ARF may inform the design of prospective clinical trials,
improving sample size or effect size estimates and potentially
guiding a stratified randomization.
As expected, the models derived from the PICARD data
themselves demonstrated marginally superior performance
characteristics when compared with other models. Of the
Table 5 | (a) Areas under ROC curve for selected generic and
disease-specific modelsa and (b) likelihood ratios for selected
generic and disease-specific modelsb
Model
Day of ARF
diagnosis
Day of
consultation
Day of first
procedure
(a)
PICARD 0.62 0.68* 0.72w
CCF 0.58 0.65 0.68
APACHE II 0.63 0.66* 0.67w
APACHE III 0.66 0.70* 0.67
Brussels 0.55 0.51 0.48
Lian˜o 0.53 0.56 0.55
LOD 0.64 0.66 0.65w
MOD 0.62 0.67* 0.70w
MPM 0.56 0.60* 0.59
SAPS II 0.69 0.70 0.71w
SHARF 0.56 0.57 0.60w
SOFA 0.64 0.70* 0.73w
SOFA (NR) 0.62 0.65* 0.68w
(b)
PICARD 23.3 47.1 33.4
CCF 1.9 14.0 20.0
APACHE II 6.8 21.5 9.6
APACHE III 13.2 32.3 13.6
Brussels 3.5 0.6 0.6
Lian˜o 2.1 5.2 3.0
LOD 10.6 16.7 4.1
MOD 5.8 17.5 8.3
MPM 2.6 13.6 6.3
SAPS II 24.4 29.5 18.4
SHARF 3.7 4.8 4.6
SOFA 10.2 38.7 30.1
SOFA (NR) 6.2 19.2 11.6
APACHE, acute physiology and chronic health evaluation; ARF, acute renal failure;
CCF, Cleveland Clinic Foundation; LOD, logistic organ dysfunction score; MOD,
multiple organ dysfunction score; MPM, mortality probability model; PICARD,
Program to Improve Care in Acute Renal Disease; ROC, receiver operating
characteristic; SAPS, simplified acute physiology score; SHARF, Stuivenberg Hospital
Acute Renal Failure; SOFA, sequential organ failure assessment; SOFA (NR), SOFA
with no renal points.
aNote: Comparisons within models by time frame.
*Day of consultation significantly higher than the day of ARF diagnosis.
wDay of first procedure significantly higher than the day of consultation for the
subset of patients who were dialyzed.
bNote: Likelihood ratios are derived from proportional hazards models.
A higher likelihood ratio indicates better model discrimination.
Table 6 | Predictors of mortality using time-dependent cov-
ariates
Parameter
Cox model RR 95% CI
Age (per decade) 1.13 1.01–1.26
Sepsisa 1.87 1.33–2.63
CNS failurea 4.58 3.30–6.35
Cardiovascular failurea 4.50 3.11–6.51
Liver failurea 1.90 1.34–2.71
Hematologic failurea 1.46 1.01–2.10
Dialysisb 1.79 1.21–2.66
CI, confidence interval; CNS, central nervous system; RR, relative risk.
aSepsis status and organ system failure updated daily, last value carried forward
where missing.
bDialysis status carried forward after initiation.
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generic severity scores, the SOFA score performed best in this
cohort. Of the disease-specific severity scores, the CCF score
performed best, particularly among patients requiring
dialysis, the subtype of patients in whom the CCF score
was derived.9 Other frequently cited severity scores for ARF
in the ICU, including those derived by Lian˜o12 and others,
performed poorly with attempted cross-validation in the
PICARD cohort. To determine whether the models derived
here are ‘overfit’ (i.e., uniquely predictive in the current data
set), the PICARD models will require cross-validation in
other populations. As PICARD included patients from five
medical centers and encompassed considerable heterogeneity
in patient characteristics,19 models derived from PICARD
may be less prone to overfitting than similar models derived
from individual centers.5,7,14
There are several important theoretical advantages to
disease-specific predictive models in critical illness. Virtually
all generic severity scores include ‘points’ for ARF; in an ARF
cohort, these points are assigned equivalently to all persons,
limiting the value of the information. Moreover, clinical or
laboratory indicators of injury may reflect different compli-
cations in cohorts depending on disease stage. For example,
in several studies of ARF in the ICU,3,15,20–22 a lower serum
creatinine concentration has been associated with increased
mortality, possibly reflecting reduced creatinine generation
owing to diminished muscle mass (associated with advanced
age, wasting, or other acute or chronic disease) or possibly
reflecting hemodilution owing to volume overload.23 Generic
severity scores would classify patients with higher serum
creatinine as higher risk.
Prior studies on risk assessment in ARF have yielded
conflicting results.8,10,11,20,24 In part, these differences reflect the
inclusion populations and the time point selected for the
evaluation of risk factors (typically the day of nephrology
consultation or first procedure). Some prior studies have
demonstrated an increased risk in older vs younger individuals,
and in men relative to women; these associations have not been
shown consistently.16 Most studies have demonstrated a strong
link between extra-renal organ system failure and the risk of
death with ARF in the ICU, propagating the notion that
persons die with, rather than from ARF. However, studies in
which patients were followed relatively early in the disease
course suggest an association between the severity of ARF
(indicated by the provision of dialysis, often with oliguria) and
mortality. These and other epidemiological data strongly
suggest some persons indeed die of, not only with, ARF.25–27
There are several strengths to the analyses presented here.
The PICARD study employed multiple sites and a relatively
large number of patients were studied. Longitudinal data
were collected, affording the investigators the ability to
examine multiple time points. The study design allowed the
determination of a predictive model at the time of ARF
diagnosis. Although this point coincided with the day of
hospitalization, ICU admission, and consultation in some
patients, it preceded consultation in two-thirds of the cases.
We demonstrate that models derived very early in the course
of ARF do not discriminate mortality well, possibly reflecting
the lack of specificity of current definitions of ARF. Never-
theless, providing a uniform time zero to track the course of
ARF independent of the timing of consultation diminishes
bias considerably, and permits evaluation of time-varying
exposures, the latter allowing risk stratification with less
misclassification. For example, among all patients with sepsis
and ARF, certain individuals will resolve sepsis over several
days with antibiotics and supportive therapy. Others will
develop progressive septic shock and other end-organ
complications refractory to conventional therapy. Use of
static exposure data would misclassify the former patients,
and correctly classify the latter. If disseminated intravascular
coagulation were to develop in the wake of sepsis, it would
not be identified as a risk factor with traditional analysis, and
sepsis or oliguria or another factor associated with dis-
seminated intravascular coagulation might be ‘credited’ with
increased risk using the static models. This process of
integrating exposure data over the course of ARF should
improve prognostic stratification in subsequent cohort
studies, and may be useful in clinical trial design, depending
on the timing of the intended intervention.
There are also several important limitations. While serving
diverse and distinct patient populations, all PICARD sites are
tertiary-care academic medical centers, and the average level
of acuity among ICU patients may be higher than in non-
tertiary care settings. Conversely, as we required informed
consent from all patients (or surrogates) and a significant
fraction of patients died before consent could be obtained,21
some of the sickest patients with ARF in the ICU may have
not been included in the PICARD cohort. Cross-validation of
the PICARD models will be required to assess their relative
performance and generalizability. Many other variables not
presented in the models reviewed here were collected in
PICARD and examined for their relation with mortality.
Selected data elements were missing in a majority of patients
(e.g., central pressures from pulmonary artery catheters).
Thus, many variables could not be included in population-
wide predictive models because of power considerations and
to abrogate bias. The models presented here may be the most
generalizable of potential models, but other clinical and
laboratory variables may be important in settings in which
they are available. For example, impaired nutritional status is
known to be associated with mortality and morbidity in
acute and chronic kidney disease, and we were able to capture
relatively little information on protein and energy intake or
resting energy expenditure. Additional subgroup analyses
(e.g., among patients with pulmonary artery catheters or
indirect calorimetry) may be of interest, but are beyond the
scope of this report.
In summary, we provide a series of three static models
predicting mortality after ARF. These models can be used for
risk adjustment when evaluating other patient characteristics
or treatment strategies at specific key time points (e.g., upon
initiation of dialysis). In addition, we provide an integrated
model examining risk factors for mortality, which included
1124 Kidney International (2006) 70, 1120–1126
o r i g i n a l a r t i c l e GM Chertow et al.: Mortality after acute renal failure
advanced age, sepsis, central nervous system, cardiovascular,
hematological, and hepatic organ system failure as well as the
severity of ARF (as indicated by the need for dialysis, or rising
serum creatinine and reduced urine output). These findings
should be validated in other large, diverse patient popula-
tions, in conjunction with the evaluation of new biomarkers,
to help inform the design and implementation of rando-
mized clinical trials in ARF.
MATERIALS AND METHODS
Study participants
The PICARD network is comprised of five academic medical centers
in the United States: University of California San Diego (Coordinat-
ing Center), CCF, Maine Medical Center, Vanderbilt University, and
University of California San Francisco). Over a 31-month period
(February 1999 to August 2001), all patients consulted for ARF in
the ICU were evaluated by PICARD study personnel for potential
study participation. Given the large number of ICU beds at CCF,
one in six ARF patients were randomized for possible study
inclusion, to avoid single center over-representation. ARF was
defined as an increase in serum creatinineX0.5 mg/dl with baseline
serum creatinine o1.5 mg/dl, or an increase in serum creatinine
X1.0 mg/dl with baseline serum creatinine X1.5 mg/dl and
o5.0 mg/dl. Patients with a baseline serum creatinine X5.0 mg/dl
were not considered for study inclusion. Baseline CKD was defined
as an estimated glomerular filtration rate o30 ml/min/1.73 m2
(corresponding to National Kidney Foundation Kidney Disease
Quality Outcomes Initiative (K/DOQI) stage IV CKD). For each
patient, the day on which ARF was identified and diagnosed by the
above criteria was designated the ARF diagnosis date. The ARF
diagnosis date may or may not have coincided with the nephrology
consultation date, or with the date of first procedure (dialysis or
hemodiafiltration) among individuals who required dialysis. Vital
signs, hemodynamic, and laboratory data were recorded on or
before the ARF diagnosis date, up to 3 days before nephrology
consultation, and daily thereafter. Multiple generic and ARF-specific
severity scores were calculated, also longitudinally. Organ failure and
related parameters were defined using validated published criteria.19
The timing, modality, and intensity of dialysis were determined by
the treating physician with no influence from study personnel.
A detailed description of PICARD inclusion and exclusion
criteria, data elements, data collection, and management strategies
are described elsewhere.28 Patients who were contacted by study
personnel and who signed (or whose proxy signed) informed
consents were enrolled in the study cohort. The reason for non-
enrollment was determined for patients who did not sign informed
consent,29 although no additional data were collected for privacy
considerations. The Committees on Human Research at each
participating clinical site approved the study protocol and informed
consent. In-hospital mortality within 60 days after ARF diagnosis
was the principal outcome of interest.
Statistical analysis
Continuous variables were expressed as mean7s.d. or median and
compared using analysis of variance (general linear models with
adjustment for multiple comparisons) or the Kruskal–Wallis test
where appropriate. Categorical variables were expressed as propor-
tions and compared with the Cochran–Mantel–Haenszel w2 test or
Fisher’s exact test. Logistic regression was employed to determine
the odds of in-hospital mortality within 60 days after ARF diagnosis,
incorporating exposure data on the day of ARF diagnosis, the day of
nephrology consultation, and among patients requiring dialysis, the
day of first procedure. Proportional hazards (‘Cox’) regression was
used to determine the association of baseline exposures with time to
death within 60 days. Finally, proportional hazards regression was
extended to incorporate time-varying covariates, to take advantage
of serially collected data, including vital signs, laboratory tests, organ
system failure, and the provision of dialysis.
For continuous variables, values were initially categorized into
quintiles to evaluate for linear vs non-linear associations with
mortality. Where associations were not linear, clinically meaningful
cutoffs were used to dichotomize the data, and indicator variables
were included in regression models. Discrete data were coded as
present or not present, and in time-dependent models, variables
could change over time (e.g., with the development or recovery of
organ system failure).
Multivariable logistic and proportional hazards regression
models were constructed with backward variable selection, using
Po0.05 for variable retention. Effect modification was evaluated by
including multiplicative interaction terms for selected variables.
Factors not included in multivariable models were re-entered
individually to evaluate for residual confounding. For time-varying
covariate models, we used the last value carried forward approach to
handle missing data elements. For patients who required dialysis,
moving average values for urine output, serum creatinine, and BUN
were used to avoid confounding by the direct effects of dialysis on
parameters of kidney function. Once dialysis was initiated, an ‘on-
dialysis’ status was carried forward regardless of the frequency or
intensity of dialysis therapy.
In logistic regression models, discrimination was assessed using
the area under the ROC curve. Calibration was assessed using the
Hosmer–Lemeshow goodness-of-fit test. The Hosmer–Lemeshow test
compares model performance (observed vs expected) across deciles of
risk, to test whether the model is biased (i.e., performs differentially
at the extremes of risk). A nonsignificant value for the Hosmer–
Lemeshow w2 suggests an absence of such bias. In proportional
hazards regression models, the relative discrimination of alternative
models was assessed using the likelihood ratio test. Plots of log (log
(survival rate)) against log (survival time) were performed to establish
the validity of the proportionality assumption.
Two-tailed P-values o0.05 were considered significant. Statistical
analyses were conducted using SAS 8.2 (SAS Institute, Cary, NC, USA).
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